TFF Pharmaceuticals, Inc. Common Stock
TFFP
TFFP was delisted on the 12th of December, 2024.
39 hedge funds and large institutions have $99.6M invested in TFF Pharmaceuticals, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 3 closing their positions.
932% more capital invested
Capital invested by funds: $9.65M → $99.6M (+$89.9M)
833% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 3
179% more funds holding
Funds holding: 14 → 39 (+25)
94% more call options, than puts
Call options by funds: $3.28M | Put options by funds: $1.69M
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$13.3M |
| 2 |
CA
Corriente Advisors
Fort Worth,
Texas
|
+$12M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3M |
| 4 |
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO)
Austin,
Texas
|
+$2.49M |
| 5 |
BlackRock
New York
|
+$2.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$311K |
| 2 |
MFIM
Mesirow Financial Investment Management
Chicago,
Illinois
|
-$219K |
| 3 |
Millennium Management
New York
|
-$115K |
| 4 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
-$79.6K |
| 5 |
BFM
Boothbay Fund Management
New York
|
-$72K |
TFFP Hedge Fund Activity: Q3 2020 in Review
39 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in TFF Pharmaceuticals, Inc. Common Stock (TFFP) for Q3 2020, worth a combined $99.6M — up 932% from $9.65M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new TFFP positions and 3 closed out — a net gain of 25 holders — while 4 added to existing stakes and 7 trimmed.
The largest buyer was Nantahala Capital Management, adding an estimated $13.3M. The largest seller was Renaissance Technologies, cutting an estimated $311K.
- 39 institutional investors held TFF Pharmaceuticals, Inc. Common Stock (TFFP) as of Q3 2020, up from 14 in Q2 2020.
- Funds reported $99.6M of TFF Pharmaceuticals, Inc. Common Stock stock for Q3 2020, up 932% quarter-over-quarter.
- 28 funds opened new TFF Pharmaceuticals, Inc. Common Stock positions in Q3 2020 and 3 closed out, a net change of +25 holders.
- The largest TFF Pharmaceuticals, Inc. Common Stock buyer in Q3 2020 was Nantahala Capital Management, an estimated $13.3M added.
- The largest TFF Pharmaceuticals, Inc. Common Stock seller in Q3 2020 was Renaissance Technologies, an estimated $311K sold.
Based on aggregated 13F filings for Q3 2020.